An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source

NCT05368818 · clinicaltrials.gov ↗

COMPLETED

Status

767

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

OTHER: Secukinumab

Sponsor

Novartis Pharmaceuticals